Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Evofosfamide |
Trade Name | |
Synonyms | TH-302 |
Drug Descriptions |
Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases a DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors, potentially providing antineoplastic activity with reduced systemic toxicity (PMID: 32787454, PMID: 31431383). |
DrugClasses | Chemotherapy - Alkylating 18 |
CAS Registry Number | 918633-87-1 |
NCIT ID | C71722 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Dexamethasone + Evofosfamide | Bevacizumab Dexamethasone Evofosfamide | 0 | 0 |
Bevacizumab + Evofosfamide | Bevacizumab Evofosfamide | 0 | 2 |
Dexamethasone + Evofosfamide | Dexamethasone Evofosfamide | 0 | 0 |
Evofosfamide | Evofosfamide | 0 | 2 |
Evofosfamide + Ipilimumab | Evofosfamide Ipilimumab | 0 | 1 |
Evofosfamide + Pazopanib | Evofosfamide Pazopanib | 0 | 1 |
Evofosfamide + Sorafenib | Evofosfamide Sorafenib | 0 | 1 |